Outlook Therapeutics (OTLK) risk factors
Item 1A of every Outlook Therapeutics, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors67 risks1 new3 dropped10 reworded
Outlook Therapeutics faces heightened risks regarding third-party payor coverage and reimbursement uncertainties for newly approved therapeutic alternatives like LYTENAVA. Global macroeconomic volatility and tariffs could adversely affect ongoing commercialization efforts for ONS-5010/LYTENAVA. GMS Ventures increased its beneficial ownership stake in the company to 41.9%, exerting significant control over corporate decisions.
Filed Dec 19, 2025 - FY2024 10-K risk factors69 risks
The company relies heavily on the success of its sole approved product candidate, ONS-5010/LYTENAVA, facing substantial cash burn and ongoing capital needs. Clinical development hurdles, intellectual property protections, and heavy dependence on single-source suppliers dominate the operational risk profile.
Filed Dec 27, 2024